Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus OTICAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus OTICAIR.
BREO ELLIPTA vs OTICAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication; fluocinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, reducing prostaglandin and leukotriene synthesis, thereby suppressing inflammation.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
1-2 sprays into each affected ear twice daily for 7 days. Topical route.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
4.2 hours; prolonged in renal impairment (up to 12 hours in creatinine clearance <30 mL/min)
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal: 85% unchanged; biliary/fecal: 10%
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Otic Antibiotic/Corticosteroid